Technological Prospection on the Medicinal Use of Cannabis sativa for the Treatment of Covid-19
DOI:
https://doi.org/10.9771/cp.v16i2.51372Keywords:
Medicinal Cannabis, Long Covid, Phytocannabinoids.Abstract
Covid-19 is characterized by organ dysfunctions which can affect the patient's quality of life and generate an overload in the public health system. Medicinal Cannabis has been aroused interest in the scientific community, as researches have been proved its safety, efficacy, reestablishment of homeostasis and, consequently, demedication. Therefore, the objective of this study was to verify the scientific and technological development on the medicinal use of Cannabis-based products. The syntax used to access the data was (COVID AND CANNAB+) /TI/AB/CLMS, and keywords cannabinoid, cannabidiol in the title, abstract and claims search fields. 24 patent documents were found, deposited especially in the United States by companies and Universities. Technological development has shown the therapeutic potential of Cannabis. There is a trend towards increasing investment in drug development by using Cannabis, which points to promising studies in this area.
Downloads
References
AL-ALY, Z.; XIE, Y.; BOWE, B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature, [s.l.], v. 594, n. 7.862, 2021.
ANDRADE, B. S. et al. Long-covid and post-covid health complications: An up-to-date review on clinical conditions and their possible molecular mechanisms. Viruses, [s.l.], 2021.
BRASIL. Agência Nacional de Vigilância Sanitária. Resolução da Diretoria Colegiada – RDC n. 327, de 9 de dezembro de 2019. Diário Oficial da União, 11 dezembro 2019. Disponível em: https://www.in.gov.br/en/web/dou/-/resolucao-da-diretoria-colegiada-rdc-n-327-de-9-de-dezembro-de-2019-232669072. Acesso em: 15 set. 2022.
BRASIL. Agência Nacional de Vigilância Sanitária. NT 01-2017-Metavyl. 2017. Disponível em: https://www.gov.br/anvisa/pt-br/setorregulado/regularizacao/medicamentos/fitoterapicos-dinamizados-e-especificos/informes/especificos/nt-01-2017-mevatyl.pdf/view. Acesso em: 30 set. 2022.
BRASIL. Constituição da República Federativa do Brasil: promulgada em 5 de outubro de 1988. Brasília: Senado Federal, 1988. Disponível em http://www.planalto.gov.br/ccivil_03/constituicao/constituicao.htm. Acesso em: 15 set. 2022.
BRASIL. Presidência da República. Casal Civil. Lei n. 9.279, de 14 de maio de 1996. Regula direitos e obrigações relativos à propriedade industrial. Disponível em: http://www.planalto.gov.br/ccivil_03/leis/l9279.htm. Acesso em: 30 set. 2022.
CASCELLA, M. et al. Features, Evaluation and Treatment Coronavirus (COVID-19) - StatPearls – NCBI Bookshelf: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2022.
CENTERS FOR DISEASE CONTROL AND PREVENTION. Long Covid or Post-COVID Conditions. 2022. Disponível em: https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html. Acesso em: 30 set. 2022.
CLINICALTRIALS.ORG. Feasibility of Cannabidiol for the Treatment of Long COVID. 2021. Disponível em: https://clinicaltrials.gov/ct2/show/NCT04997395. Acesso em: 30 set. 2022.
CRIPPA, J. A. S. et al. Cannabidiol for COVID-19 Patients with Mild to Moderate Symptoms (CANDIDATE Study): A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Cannabis Cannabinoid Res., [s.l.], Oct 7, 2021. DOI: 10.1089/can.2021.0093. Epub ahead of print. PMID: 34619044.
CROCQ, M. A. History of cannabis and the endocannabinoid system. Dialogues in Clinical Neuroscience, [s.l.], v. 22, n. 3, 2020.
DOWELL, D.; HAEGERICH, T. M.; CHOU, R. CDC guideline for prescribing opioids for chronic pain-United States, 2016. JAMA – Journal of the American Medical Association, [s.l.], v. 315, n. 15, 2016.
GONEN, T.; AMITAL, H. Cannabis and cannabinoids in the treatment of rheumatic diseases. Rambam Maimonides Medical Journal, [s.l.], v. 11, n. 1, 2020.
GROOM, Q. R. C. Clarke & M. D. Merlin (2013) – Cannabis: Evolution and Ethnobotany. Plant Ecology and Evolution, [s.l.], v. 147, n. 1, 2014.
HALEEM, A.; JAVAID, M.; VAISHYA, R. Effects of COVID-19 pandemic in daily life. Current Medicine Research and Practice, [s.l.], v. 10, n. 2, 2020.
HIRANO, T.; MURAKAMI, M. COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release Syndrome. Immunity, [s.l.], v. 52, n. 5, 2020.
HOLST, M.; NOWAK, D.; HOCH, E. Cannabidiol As a Treatment for COVID-19 Symptoms? A Critical Review. Cannabis Cannabinoid Res., [s.l.], Jul 26, 2022. DOI: 10.1089/can.2021.0135. Epub ahead of print. PMID: 35881839.
HU, B.; HUANG, S.; YIN, L. The cytokine storm and COVID-19. Journal of Medical Virology, [s.l.], 2021.
HUSSAIN, T. et al. Cannabis sativa research trends, challenges, and new-age perspectives. iScience, [s.l.], 2021.
IFFLAND, K.; GROTENHERMEN, F. An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies. Cannabis and cannabinoid research, [s.l.], 2017.
JOHN, J. et al. A Case of Cannabis-induced Acute Pancreatitis. Cureus, [s.l.], 2019.
JORNAL DA USP. Pesquisa avalia Canabidiol no tratamento de pacientes com COVID longa. 2021. Disponível em: https://jornal.usp.br/ciencias/pesquisa-avalia-canabidiol-no-tratamento-de-pacientes-com-covid-longa/. Acesso em: 30 set. 2022.
KHODADADI, H. et al. Cannabidiol Modulates Cytokine Storm in Acute Respiratory Distress Syndrome Induced by Simulated Viral Infection Using Synthetic RNA. Cannabis and Cannabinoid Research, [s.l.], v. 5, n. 3, 2020.
LAKE, S.; SOCÍAS, M. E.; MILLOY, M. J. Evidence shows that cannabis has fewer relative harms than opioids. CMAJ, [s.l.], 2020.
LANDA, E. et al. Cannabis-induced Acute Coronary Syndrome: A Coincidence or Not? Cureus, [s.l.], 2019.
LIM, K.; SEE, Y. M.; LEE, J. A systematic review of the effectiveness of medical cannabis for psychiatric, movement and neurodegenerative disorders. Clinical Psychopharmacology and Neuroscience, [s.l.], 2017.
MACCALLUM, C. A.; RUSSO, E. B. Practical considerations in medical cannabis administration and dosing. European Journal of Internal Medicine, [s.l.], 2018.
MINISTÉRIO DA CIÊNCIA, TECNOLOGIA E INOVAÇÕES. Chamada Pública prevê R$27 milhões para pesquisa sobre COVID longa. 2022. Disponível em: https://www.gov.br/mcti/pt-br/acompanhe-o-mcti/noticias/2022/08/chamada-publica-preve-r-27-milhoes-para-pesquisa-sobre-covid-longa#:~:text=Covid%20longa%20%2D%20Segundo%20a%20chamada,causa%20a%20COVID%2D19%E2%80%9D. Acesso em: 30 set. 2022.
MURAKAMI, M.; KAMIMURA, D.; HIRANO, T. Pleiotropy and Specificity: Insights from the Interleukin 6 Family of Cytokines. Immunity, [s.l.], 2019.
NGUYEN, L. C. et al. Cannabidiol inhibits SARS-CoV-2 replication through induction of the host ER stress and innate immune responses. Science Advances, [s.l.], v. 8, n. 8, 2022.
OGUNTIBEJU, O. O. Type 2 diabetes mellitus, oxidative stress and inflammation: examining the links. International journal of physiology, pathophysiology and pharmacology, [s.l.], v. 11, n. 3, 2019.
QUESTEL ORBIT. [Base de dados – Internet]. Questel Orbit Inteligence. 2022. Disponível em: https://www.orbit.com. Acesso em: 15 set. 2022.
RIBEIRO, A. et al. Cannabidiol, a non-psychotropic plant-derived cannabinoid, decreases inflammation in a murine model of acute lung injury: Role for the adenosine A 2A receptor. European Journal of Pharmacology, [s.l.], v. 678, n. 1-3, 2012.
RONG, C. et al. Cannabidiol in medical marijuana: Research vistas and potential opportunities. Pharmacological Research, [s.l.], 2017.
RUSSO, E. B. et al. Phytochemical and genetic analyses of ancient cannabis from Central Asia. Journal of Experimental Botany, [s.l.], v. 59, n. 15, 2008.
SMALL, E. Evolution and Classification of Cannabis sativa (Marijuana, Hemp) in Relation to Human Utilization. Botanical Review, [s.l.], v. 81, n. 3, 2015.
THE GREEN HUB. Inovação e empreendedorismo na indústria da Cannabis. 2020. Disponível em: https://thegreenhub.com.br/inovacao-e-empreendedorismo-na-industria-da-cannabis/. Acesso em: 16 nov. 2022.
VAN BREEMEN, R. B. et al. Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants. Journal of Natural Products, [s.l.], v. 85, n. 1, 2022.
WANG, B. et al. In search of preventive strategies: novel high-CBD Cannabis sativa extracts modulate ACE2 expression in COVID-19 gateway tissues. Aging, [s.l.], v. 12, n. 22, 2020.
WHO – WORLD HEALTH ORGANIZATION. Post Covid-19 condition (Long COVID). 2022. Disponível em: https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition. Acesso em 16 nov. 2022.
ZHOU, Y. et al. Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus. BioRxiv, [s.l.], 2020.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Cadernos de Prospecção
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
O autor declara que: - Todos os autores foram nomeados. - Está submetendo o manuscrito com o consentimento dos outros autores. - Caso o trabalho submetido tiver sido contratado por algum empregador, tem o consentimento do referido empregador. - Os autores estão cientes de que é condição de publicação que os manuscritos submetidos a esta revista não tenham sido publicados anteriormente e não sejam submetidos ou publicados simultaneamente em outro periódico sem prévia autorização do Conselho Editorial. - Os autores concordam que o seu artigo ou parte dele possa ser distribuído e/ou reproduzido por qualquer forma, incluindo traduções, desde que sejam citados de modo completo esta revista e os autores do manuscrito. - Revista Cadernos de Prospecção está licenciado com uma Licença Creative Commons Attribution 4.0. Esta licença permite que outros remixem, adaptem e criem a partir do seu trabalho para fins não comerciais, e embora os novos trabalhos tenham de lhe atribuir o devido crédito e não possam ser usados para fins comerciais, os usuários não têm de licenciar esses trabalhos derivados sob os mesmos termos.
Este obra está licenciado com uma Licença Creative Commons Atribuição 4.0 Internacional.
